The impact of an AI tool on diagnostic accuracy, review time, and diagnostic confidence in detecting acute abnormalities in non-contrast CT head scans: a study among emergency medicine clinicians, general radiologists, and radiographers

ISRCTN ISRCTN17560291
DOI https://doi.org/10.1186/ISRCTN17560291
IRAS number 310995
ClinicalTrials.gov number NCT06018545
Secondary identifying numbers IRAS 310995
Submission date
07/09/2023
Registration date
16/10/2023
Last edited
16/10/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Injury, Occupational Diseases, Poisoning
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
The study aims to evaluate the impact of an AI tool called qER 2.0 EU on the diagnostic accuracy, speed, and confidence of healthcare professionals who review non-contrast CT head scans. The study will involve 30 readers, including general radiologists, emergency medicine clinicians, and CT radiographers, who will interpret 150 non-contrast CT head scans, first without and then with the assistance of the AI tool. The scans will include 60 control cases and 90 abnormal cases with intracranial haemorrhage, brain infarct, midline shift, or skull fracture. The study will assess the stand-alone performance of the AI tool and its impact on the readers' performance.

Who can participate?
Emergency medicine consultants and registrars, general radiologist consultants and registrars, and CT radiographers who review CT head scans as part of their clinical practice.

What does the study involve?
30 readers will be recruited across four NHS trusts including ten general radiologists, fifteen EM clinicians, and five CT radiographers of varying seniority. Readers will interpret each scan first without, then with, the assistance of the qER 2.0 EU AI tool, with an intervening 4-week washout period. Using a panel of neuroradiologists as ground truth, the stand-alone performance of qER will be assessed, and its impact on the readers’ performance will be analysed as change in accuracy, mean review time per scan, and self-reported diagnostic confidence.

What are the possible benefits and risks of participating?
None

Where is the study run from?
Oxford University Hospitals NHS Trust (UK)

When is the study starting and how long is it expected to run for?
October 2022 to October 2024

Who is funding the study?
This work was supported by the NHSX AI in Health and Care Award (UK)

Who is the main contact?
Prof. Alex Novak, alex.novak@ouh.nhs.uk

Contact information

Prof Alex Novak
Principal Investigator

Headley Way
Headington
Oxford
OX3 9DU
United Kingdom

ORCiD logoORCID ID 0009-0006-4086-3152
Phone +44 7944 653970
Email alex.novak@ouh.nhs.uk

Study information

Study designObservational cohort study that is retrospective multicenter and multireader
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital, Medical and other records
Study typeOther, Efficacy
Participant information sheet 44254 STEDI2 AI-REACT study PIS V1.0 29Nov2022.pdf
Scientific titleAI Assisted Reader Evaluation in Acute Computed Tomography (CT) head interpretation (AI-REACT)
Study acronymAI-REACT
Study hypothesisThe purpose of the study is to assess the impact of an Artificial Intelligence (AI) tool called qER 2.0 EU on the performance of readers, including general radiologists, emergency medicine clinicians, and radiographers, in interpreting non-contrast CT head scans. The study aims to evaluate the changes in accuracy, review time, and diagnostic confidence when using the AI tool. It also seeks to provide evidence on the diagnostic performance of the AI tool and its potential to improve efficiency and patient care in the context of the National Health Service (NHS). The study will use a dataset of 150 CT head scans, including both control cases and abnormal cases with specific abnormalities. The results of this study will inform larger follow-up studies in real-life Emergency Department (ED) settings.
Ethics approval(s)

Approved 13/12/2022, Research Ethics Committee of the Central University (CUREC) and the Interdivisional Research Ethics Committee of Medical Sciences (IDREC) (Churchill Drive, Headington, Oxford, OX3 7GB, United Kingdom; +44 1865 (6)16577; ethics@medsci.ox.ac.uk), ref: R80145/RE002

ConditionExtradural haemorrhage, Subdural haemorrhage, Subarachnoid haemorrhage, Intraparenchymal haemorrhage, Intraventricular haemorrhage, Brain infarct or stroke, Intracraneal Mass effect, Skull fractures
InterventionA retrospective dataset of 150 non-contrast CT head scans will be compiled, to include 60 control cases and 90 abnormal cases with intracranial haemorrhage, brain infarct, midline shift or skull fracture. The intracranial haemorrhage cases will be sub-classified into extradural, subdural, subarachnoid, intraparenchymal, and intraventricular.
30 readers will be recruited across four NHS trusts including ten general radiologists, fifteen EM clinicians, and five CT radiographers of varying seniority. Readers will interpret each scan first without, then with, the assistance of the qER 2.0 EU AI tool, with an intervening 4-week washout period. Using a panel of neuroradiologists as ground truth, the stand-alone performance of qER will be assessed, and its impact on the readers’ performance will be analysed as change in accuracy, mean review time per scan, and self-reported diagnostic confidence. Subgroup analyses will be performed by reader professional group, reader seniority, pathological finding, and neuroradiologist-rated difficulty.
Intervention typeOther
Primary outcome measureReader and qER performance will be evaluated as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Area Under Receiver Operating Characteristic Curve (AUC). Reader performance will be evaluated with and without AI assistance. Reader speed will be evaluated as the mean review time per scan, with and without AI assistance.
Secondary outcome measuresReader confidence will be evaluated as self-reported diagnostic confidence on a 10 point visual analogue scale, with 0 being not completely confident, and 10 being totally confident, evaluated with and without AI assistance.
Overall study start date01/10/2022
Overall study end date02/10/2024

Eligibility

Participant type(s)Health professional
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants30
Total final enrolment30
Participant inclusion criteriaEmergency medicine consultants and registrars, general radiologist consultants and registrars, and CT radiographers who review CT head scans as part of their clinical practice
Participant exclusion criteria1. Neuroradiologists
2. (Non-radiologist groups) Clinicians with previous formal postgraduate CT reporting training
3. (Emergency Medicine group) Clinicians with previous career in radiology/neurosurgery to registrar level
Recruitment start date27/06/2023
Recruitment end date04/08/2023

Locations

Countries of recruitment

  • England
  • Scotland
  • United Kingdom

Study participating centres

Oxford University Hospitals NHS Foundation Trust
John Radcliffe Hospital
Headley Way
Headington
Oxford
OX3 9DU
United Kingdom
Guy's and St Thomas' NHS Foundation Trust
St Thomas' Hospital
Westminster Bridge Road
London
SE1 7EH
United Kingdom
Northumbria Healthcare NHS Foundation Trust (headquarters)
Rake Lane
North Shields
NE29 8NH
United Kingdom
NHS Greater Glasgow and Clyde
J B Russell House
Gartnavel Royal Hospital
1055 Great Western Road Glasgow
Glasgow
G12 0XH
United Kingdom

Sponsor information

Oxford University Hospitals NHS Trust
Hospital/treatment centre

John Radcliffe Hospital
Headley Way
Headington
Oxford
OX3 9DU
England
United Kingdom

Phone +44 300 304 7777
Email palsjr@ouh.nhs.uk
Website https://www.ouh.nhs.uk
ROR logo "ROR" https://ror.org/03h2bh287

Funders

Funder type

Government

NHS transformation directorate (NHSX)

No information available

Results and Publications

Intention to publish date01/10/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryPublished as a supplement to the results publication
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planAll data generated or analysed during this study will be included in the subsequent results publication

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet version 1.0 29/11/2022 12/09/2023 No Yes
Protocol file 12/09/2023 No No

Additional files

44254 STEDI2 AI-REACT study PIS V1.0 29Nov2022.pdf
44254 AI-REACT Protocol.pdf

Editorial Notes

12/09/2023: Trial's existence confirmed by NHS HRA.